|
1
|
Von Pawel J: Gefitinib (Iressa, ZD 1839):
a novel targeted approach for the treatment of solid tumors. Bull
Cancer. 91:E70–E76. 2004.PubMed/NCBI
|
|
2
|
Cerosimo RJ: Gefitinib: an adverse effects
profile. Expert Opin Drug Saf. 5:469–479. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fukuoka M, Yano S, Giaccone G, et al:
Multi-institutional randomized phase II trial of gefitinib for
previously treated patients with advanced non-small-cell lung
cancer. J Clin Oncol. 21:2237–2246. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Giaccone G, Herbst RS, Manegold C, et al:
Gefitinib in combination with gemcitabine and cisplatin in advanced
non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin
Oncol. 22:777–784. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Herbst RS, Giaccone G, Schiller JH, et al:
Gefitinib in combination with paclitaxel and carboplatin in
advanced non-small-cell lung cancer: a phase III trial - INTACT 2.
J Clin Oncol. 22:785–794. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ohyanagi F, Ando Y, Nagashima F, et al:
Acute gefitinib-induced pneumonitis. Int J Clin Oncol. 9:406–409.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Teramoto S, Yamamoto H and Ouchi Y:
Clinical efficacy and toxicity of gefitinib in patients with lung
cancer. Lancet. 361:1992–1993. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sumpter K, Harper-Wynne C, O’Brien M and
Congleton J: Severe acute interstitial pneumonia and gefitinib.
Lung Cancer. 43:367–368. 2004. View Article : Google Scholar
|
|
9
|
Umemura S, Kishino D, Tabata M, et al:
Systemic tumor embolism mimicking gefitinib (‘IRESSA’)-induced
interstitial lung disease in a patient with lung cancer. Intern
Med. 44:979–982. 2005.PubMed/NCBI
|
|
10
|
Suzuki M, Asahina H, Konishi J, et al:
Recurrent gefitinib-induced interstitial lung disease. Intern Med.
47:533–536. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aoe K, Hiraki A, Murakami T, et al: Sudden
onset of interstitial lung disease induced by gefitinib in a lung
cancer patient with multiple drug allergy. Anticancer Res.
25:415–418. 2005.PubMed/NCBI
|
|
12
|
Nagaria NC, Cogswell J, Choe JK and
Kasimis B: Side effects and good effects from new chemotherapeutic
agents. Case 1 Gefitinib-induced interstitial fibrosis. J Clin
Oncol. 23:2423–2424. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tian Q and Chen LA: Erlotinib achieved
partial response in a non-small cell lung cancer patient with
gefitinib-induced interstitial lung disease. Case Rep Oncol.
4:464–466. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kuo LC, Lin PC, Wang KF, et al: Successful
treatment of gefitinib-induced acute interstitial pneumonitis with
high-dose corticosteroid: a case report and literature review. Med
Oncol. 28:79–82. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Seto T, Seki N, Uematsu K, et al:
Gefitinib-induced lung injury successfully treated with high-dose
corticosteroids. Respirology. 11:113–116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ohyanagi F, Ando Y, Nagashima F,
Narabayashi M and Sasaki Y: Acute gefitinib-induced pneumonitis.
Int J Clin Oncol. 9:406–409. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kitajima H, Takahashi H, Harada K, et al:
Gefitinib-induced interstitial lung disease showing improvement
after cessation: disassociation of serum markers. Respirology.
11:217–220. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sakoda Y, Kitasato Y, Kawano Y, et al: A
case of alveolar hemorrhage caused by gefitinib. Nihon Kokyuki
Gakkai Zasshi. 49:506–510. 2011.(In Japanese).
|
|
19
|
Goto Y, Hojo M, Takeda Y, et al:
Gefitinib-induced interstitial lung disease - addition of
intravenous cyclophosphamide to corticosteroids is a valuable
treatment option: A case report. Med Oncol. 27:753–755. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fukui T, Otani S, Hataishi R, et al:
Successful rechallenge with erlotinib in a patient with EGFR-mutant
lung adenocarcinoma who developed gefitinib-related interstitial
lung disease. Cancer Chemother Pharmacol. 65:803–806. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Su Y, Peng L and Wu YM: A case of
gefitinib maintenance treatment of non-small cell lung cancer
caused by interstitial pneumonia. Chongqing Medical Journal.
40:3102011.(In Chinese).
|
|
22
|
Peng W, Gao J and Miao LY: Death from
pulmonary interstitial fibrosis and liver damage after taking
gefitinib. Adverse Drug Reactions Journal. 11:429–430. 2009.(In
Chinese).
|
|
23
|
Feng ZZ, Cao Y, Sun LM and Sun P: A cases
of Gefitinib treatment of non-small cell lung cancer with finger
bone metastasis caused interstitial pneumonia. Journal of Dalian
Medical University. 30:588–589. 2008.(In Chinese).
|
|
24
|
Cui H, Huang Q and Chen Y: A case report
of Gefitinib-induced interstitial pneumonia. J Clin Oncol.
12:235–237. 2007.
|
|
25
|
Liang H and Ynag H: A case of
Gefitinib-induced interstitial pneumonia. Practical Journal of
Medicine. 1:1622009.
|
|
26
|
Huang JH, Zhang Y and Zheng J:
Interstitial pneumonia caused by gefitinib in one patient. Chinese
Journal of New Drugs and Clinical Remedies. 26:878–879. 2007.(In
Chinese).
|
|
27
|
Wang WL and Sun Y: One case of
interstitial pneumonia caused by oral gefitinib and radiotherapy.
Pharmaceutical and Clinical Research. 16:506–507. 2008.(In
Chinese).
|
|
28
|
Zhou Y, Dai J, Zhu YZ and Chen FL:
Gefitinib-induced interstitial pneumonia CT image analysis. China
Modern Doctor. 12:61–62. 2010.(In Chinese).
|
|
29
|
Cao SF, Deng QN and Zhang DM: One case of
epidermal growth factor receptor inhibitors-IRESA induced
interstitial pneumonia. Journal of Guangdong College of Pharmacy.
20:304–305. 2004.(In Chinese).
|
|
30
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hotta K, Kiura K, Takigawa N, et al:
Comparison of the incidence and pattern of interstitial lung
disease during erlotinib and gefitinib treatment in Japanese
patients with non-small cell lung cancer: the Okayama Lung Cancer
Study Group experience. J Thorac Oncol. 5:179–184. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Min JH, Lee HY, Lim H, et al: Drug-induced
interstitial lung disease in tyrosine kinase inhibitor therapy for
non-small cell lung cancer: a review on current insight. Cancer
Chemother Pharmacol. 68:1099–1109. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Danson S, Blackhall F, Hulse P and Ranson
M: Interstitial lung disease in lung cancer: separating disease
progression from treatment effects. Drug Saf. 28:103–113. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kudoh S, Kato H, Nishiwaki Y, et al:
Interstitial lung disease in Japanese patients with lung cancer: a
cohort and nested case-control study. Am J Respir Crit Care Med.
177:1348–1357. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Armour A: Gefitinib in advanced non-small
cell lung cancer: Clinical experience in patients of Asian origin.
Asia Pac J Clin Oncol. 3:66–78. 2007. View Article : Google Scholar
|
|
36
|
American Thoracic Society; European
Respiratory Society. American Thoracic Society/European Respiratory
Society International Multidisciplinary Consensus Classification of
the Idiopathic Interstitial Pneumonias. This joint statement of the
American Thoracic Society (ATS), and the European Respiratory
Society (ERS) was adopted by the ATS board of directors, June 2001
and by the ERS Executive Committee, June 2001. Am J Respir Crit
Care Med. 15:277–304. 2002.
|
|
37
|
Zhang Y, Yang H, Zhao M and He J:
Successful treatment of gefitinib-induced acute interstitial
pneumonitis with corticosteroid and non-invasive BIPAP-ventilation.
J Thorac Dis. 4:316–319. 2012.PubMed/NCBI
|
|
38
|
Shih YN, Chiu CH, Tsai CM and Perng RP:
Interstitial pneumonia during gefitinib treatment of non-small-cell
lung cancer. J Chin Med Assoc. 68:183–186. 2005. View Article : Google Scholar : PubMed/NCBI
|
